Insmed to unveil six abstracts including late-breaking ARIKAYCE Phase 3b ENCORE results
INSM•Insmed will present six respiratory abstracts at ATS 2026 in Orlando, including late-breaking Phase 3b ENCORE results evaluating ARIKAYCE with once-daily azithromycin and ethambutol in treatment-naïve Mycobacterium avium complex lung infection. Additional data include post-hoc BRINSUPRI analysis, TPIP pharmacokinetics, PH-ILD burden findings and a seven-center bronchiectasis diagnosis quality initiative.
1. Conference presentations overview
Insmed will showcase six abstracts at the American Thoracic Society International Conference 2026 in Orlando from May 17–20, highlighting its advancing respiratory pipeline and portfolio.
2. Late-breaking ENCORE study details
The Phase 3b ENCORE abstract will present ARIKAYCE paired with once-daily azithromycin (250 mg) and ethambutol (15 mg/kg) versus placebo plus multidrug therapy in treatment-naïve adults with new Mycobacterium avium complex lung infection.
3. Additional portfolio data
Insmed will share a post-hoc analysis from the Phase 3 ASPEN trial of BRINSUPRI, real-world non-cystic fibrosis bronchiectasis experience, pharmacokinetic results for investigational treprostinil palmitil inhalation powder and disease burden findings in pulmonary hypertension associated with interstitial lung disease.
4. Bronchiectasis diagnosis quality initiative
The company is funding a seven-center independent research grant to support a large-scale electronic health record study and pilot scalable interventions aimed at improving timely and accurate bronchiectasis diagnosis across U.S. medical systems.
